A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting

This study is a retrospective, observational study to evaluate minocycline use in participants under real world conditions.

This study is a retrospective, observational study to evaluate minocycline use in participants under real world conditions.

Inclusion Criteria:

• The participant was treated with Minocin IV for a presumed or culture-confirmed gram-negative infection, as monotherapy or part of a broader regimen, for at least 48 hours.
• The participant treatment for gram-negative infection was initiated May 1, 2015, or later.
• The participant was at least 18 years old.
• This was the first course of Minocin IV administered to the participant within the study period for the treatment of gram-negative infection.
• At least 60 days has elapsed since the participant received the last dose of Minocin IV therapy for a presumed or confirmed gram-negative infection (prior to data entry into the electronic case report form, including step-down to oral therapy.

Exclusion Criteria:

• The participant received Minocin IV as a part of a controlled clinical trial.
• The participant received Minocin IV as a part of a Medicines Company- or Rempex Company-sponsored pharmacoeconomic outcomes study.
• Pregnancy (in the participant's or participant's partner) occurred after the first dose of Minocin IV through hospital discharge.
• Female participants were pregnant or nursing at the time of enrollment.